Arecor Therapeutics plc (AIM:AREC)

Market Cap	37.60M +28.5%
Revenue (ttm)	890.00K -22.9%
Net Income	190.00K
EPS	0.01
Shares Out	45.30M
PE Ratio	190.74
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,633
Open	84.89
Previous Close	80.00
Day's Range	80.00 - 85.00
52-Week Range	55.27 - 95.00
Beta	0.08
Analysts	Strong Buy
Price Target	250.50 (+201.81%)
Earnings Date	Oct 12, 2026

About Arecor Therapeutics

Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company’s lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a novel oral delivery platform using a GLP-1 receptor agonist. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 33
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AREC

Analyst Summary

According to 2 analysts, the average rating for AREC stock is "Strong Buy." The 12-month stock price target is 251p, which is an increase of 201.81% from the latest price.

Price Target

251p

(201.81% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 15, 2026

Data Sources Report a data error